MT Newswires
Truist Cuts Price Target on Boston Scientific to $95 From $120, Keeps Buy Rating
📊
AI Sentiment
Positive
7/10
- Home
- BSX
as of 02-06-2026 2:25pm EST
$76.18
$1.46
-1.88%
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 137.8B | IPO Year: | 1992 |
| Target Price: | $109.30 | AVG Volume (30 days): | 18.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.94 | EPS Growth: | 55.20 |
| 52 Week Low/High: | $74.86 - $109.50 | Next Earning Date: | 02-04-2026 |
| Revenue: | $20,074,000,000 | Revenue Growth: | 19.87% |
| Revenue Growth (this year): | 12.53% | Revenue Growth (next year): | 10.88% |
| P/E Ratio: | 40.02 | Index: | |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
Mahoney Michael F
Sell
Chairman, President & CEO
BSX Feb 2, 2026
Avg Cost/Share
$93.77
Shares
160,901
Total Value
$15,043,394.38
Owned After
1,571,436
Butcher Arthur C
Sell
EVP& Grp Pres, MedSurg & APAC
BSX Dec 1, 2025
Avg Cost/Share
$101.55
Shares
17,313
Total Value
$1,758,188.82
Owned After
23,600
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mahoney Michael F | BSX | Chairman, President & CEO | Feb 2, 2026 | Sell | $93.77 | 160,901 | $15,043,394.38 | 1,571,436 | |
| Butcher Arthur C | BSX | EVP& Grp Pres, MedSurg & APAC | Dec 1, 2025 | Sell | $101.55 | 17,313 | $1,758,188.82 | 23,600 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
TipRanks
Morning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results
📊
AI Sentiment
Positive
7/10
Medical Device Network
Boston Scientific’s shares tumble 18% despite strong FY25 growth
📉
AI Sentiment
Negative
3/10
MT Newswires
Needham Adjusts Price Target on Boston Scientific to $97 From $121, Maintains Buy Rating
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Jefferies Adjusts Price Target on Boston Scientific to $120 From $132, Maintains Buy Rating
📊
AI Sentiment
Positive
7/10
MT Newswires
Citigroup Adjusts Price Target on Boston Scientific to $102 From $130, Maintains Buy Rating
📊
AI Sentiment
Positive
7/10
MT Newswires
Stifel Adjusts Price Target on Boston Scientific to $110 From $125, Maintains Buy Rating
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
RBC Lowers Price Target on Boston Scientific to $115 From $130, Keeps Outperform Rating
📈
AI Sentiment
Highly Positive
8/10
Compare BSX vs Leading Stocks
See how BSX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.